Last reviewed 2026-05-28 · How we verify

NVX-CoV2705

Sanofi · FDA-approved active Biologic ✓ Verified May 2026 Quality 2/100

NVX-CoV2705 is a Biologic drug developed by Sanofi. It is currently FDA-approved. Also known as: Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted with Matrix-M, Omicron JN.1 subvariant SARS-CoV-2 rS vaccine adjuvanted with Matrix-M.

NVX-CoV2705 is a vaccine being studied in a Phase 3 clinical trial for the prevention of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, COVID-19, SARS-CoV-2 Infection, and Sars-CoV-2 Infection. The exact mechanism of NVX-CoV2705 is currently unknown.

At a glance

Generic name	NVX-CoV2705
Also known as	Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted with Matrix-M, Omicron JN.1 subvariant SARS-CoV-2 rS vaccine adjuvanted with Matrix-M
Sponsor	Sanofi
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

COVID-19 Reactogenicity (PHASE4)
Safety and Immunogenicity of NVX-CoV2705 (PHASE3)
Efficacy and Safety of NVX-CoV2705 (PHASE4)
A Strain Change Study for SARS-CoV-2 rS Vaccines (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NVX-CoV2705 CI brief — competitive landscape report
NVX-CoV2705 updates RSS · CI watch RSS
Sanofi portfolio CI

Frequently asked questions about NVX-CoV2705

What is NVX-CoV2705?

NVX-CoV2705 is a Biologic drug developed by Sanofi.

Who makes NVX-CoV2705?

NVX-CoV2705 is developed and marketed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is NVX-CoV2705 also known as anything else?

NVX-CoV2705 is also known as Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted with Matrix-M, Omicron JN.1 subvariant SARS-CoV-2 rS vaccine adjuvanted with Matrix-M.

What development phase is NVX-CoV2705 in?

NVX-CoV2705 is FDA-approved (marketed).

Manufacturer: Sanofi — full pipeline
Also known as: Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted with Matrix-M, Omicron JN.1 subvariant SARS-CoV-2 rS vaccine adjuvanted with Matrix-M

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing